We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

175 hedge funds and large institutions have $650M invested in Intercept Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 58 increasing their positions, 52 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 52

5% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 37

1% less funds holding

Funds holding: 177175 (-2)

25% less call options, than puts

Call options by funds: $36M | Put options by funds: $47.8M

45% less capital invested

Capital invested by funds: $1.18B → $650M (-$528M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
175
Holders Change
-2
Holders Change %
-1.13%
% of All Funds
3.1%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
35
Increased
58
Reduced
52
Closed
37
Calls
$36M
Puts
$47.8M
Net Calls
-$11.8M
Net Calls Change
-$7.54M
Name Holding Trade Value Shares
Change
Change in
Stake
DKCM
26
Davidson Kempner Capital Management
New York
$4.02M +$5.39M +162,800 New
BNP Paribas Financial Markets
27
BNP Paribas Financial Markets
France
$3.89M +$4.47M +134,775 +593%
CSS
28
Cubist Systematic Strategies
Connecticut
$3.61M +$3.6M +108,600 +289%
PA
29
Pinnacle Associates
New York
$3.31M -$291K -8,784 -6%
CS
30
Credit Suisse
Switzerland
$3.25M -$210K -6,352 -5%
DA
31
Duality Advisers
Florida
$3.2M +$3.27M +98,685 +321%
Russell Investments Group
32
Russell Investments Group
United Kingdom
$3M -$2.08M -62,772 -34%
PAMU
33
Pictet Asset Management (UK)
United Kingdom
$2.96M -$119K -3,600 -3%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$2.59M -$19.4K -585 -0.6%
PP
35
PDT Partners
New York
$2.58M -$8.02K -242 -0.2%
Millennium Management
36
Millennium Management
New York
$2.49M +$3.34M +100,708 New
N
37
Nuveen
North Carolina
$2.4M -$4.12M -124,393 -56%
Barclays
38
Barclays
United Kingdom
$2.3M -$6.81M -205,476 -69%
Principal Financial Group
39
Principal Financial Group
Iowa
$2.2M +$940K +28,379 +47%
AC
40
Antara Capital
New York
$2.07M +$2.78M +83,926 New
GC
41
Greenlight Capital
New York
$2.02M -$601K -18,144 -18%
TCM
42
Tekla Capital Management
Massachusetts
$1.9M
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$1.88M -$77.1K -2,326 -3%
Marshall Wace
44
Marshall Wace
United Kingdom
$1.81M +$1.15M +34,805 +90%
Deutsche Bank
45
Deutsche Bank
Germany
$1.8M -$7.82M -236,009 -76%
Wells Fargo
46
Wells Fargo
California
$1.79M +$837K +25,246 +54%
Man Group
47
Man Group
United Kingdom
$1.52M -$1.92M -57,979 -48%
Fisher Asset Management
48
Fisher Asset Management
Washington
$1.48M -$95.2K -2,873 -5%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.48M
AA
50
ALPS Advisors
Colorado
$1.47M +$582K +17,557 +42%

ICPT Hedge Fund Activity: Q4 2020 in Review

175 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2020, worth a combined $650M — down 45% from $1.18B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of ICPT and 35 opened new positions — a net loss of 2 holders — while 52 trimmed existing stakes and 58 added.

The largest buyer was State Street, adding an estimated $28.5M. The largest seller was Boxer Capital, exiting entirely with an estimated $48.8M sold.

  • 175 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2020, down from 177 in Q3 2020.
  • Funds reported $650M of Intercept Pharmaceuticals, Inc. stock for Q4 2020, down 45% quarter-over-quarter.
  • 35 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2020 and 37 closed out, a net change of -2 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q4 2020 was State Street, an estimated $28.5M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q4 2020 was Boxer Capital, an estimated $48.8M sold.

Based on aggregated 13F filings for Q4 2020.